South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Asian Markets Slip as AI Spending Fears Shake Tech, Wall Street Futures Rebound 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Oil Prices Slip as U.S.–Iran Talks Ease Supply Disruption Fears 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady 
MBK Partners and Unison Capital have formed a consortium to acquire Osstem Implant. They are planning to buy the management rights of the South Korean dental equipment and supplies manufacturing company.
As per The Korea Times, the stock price of Osstem implant soared after the MBK Partners and Unison Capital Korea consortium announced their intention to acquire the dental supplies firm’s management rights via a tender offer.
It was explained that a tender offer is a type of bid that is commonly made to buy a publicly traded company from shareholders. The offer asks them to sell their stock holdings at a set price and usually at a premium.
Stock market investors reportedly responded in a good way to the bid as they flocked to buy the shares. Moreover, when the news came out, Osstem Implant’s stock price once reached KRW188,000, which is said to be its highest since it went public on the KOSPI market in 2007. The stock price closed at KRW186,300, or about $151, after an increase of 14.65% from the previous session.
As for the MBK Partner and Unison Capital’s consortium, they have tendered a price offer of KRW190,000 per share. Shareholders of the company may register at NH Investment to sell off their stake through the tender offer until Feb. 24.
"As Osstem Implant is an export company and top-tier implant material provider, MBK's strong global network is expected to stably support the firm's long-term growth and continuous R&D activities, while UCK's unparalleled dental industry insights will also provide the firm with solid future growth," an insider from the local capital market told The Korea Times this week.
Meanwhile, The Korea Herald reported that if the tender offer goes ahead as planned, the consortium will become Osstem Implat’s largest shareholder. The company’s chairman Choi Kyu Ok follows in second spot with 9.6% stake ownership, while the Korea Corporate Governance Improvement is third with its 6.57% share.
